DE60028358D1 - Hmg1 antagonisten zur behandlung von entzündungen - Google Patents
Hmg1 antagonisten zur behandlung von entzündungenInfo
- Publication number
- DE60028358D1 DE60028358D1 DE60028358T DE60028358T DE60028358D1 DE 60028358 D1 DE60028358 D1 DE 60028358D1 DE 60028358 T DE60028358 T DE 60028358T DE 60028358 T DE60028358 T DE 60028358T DE 60028358 D1 DE60028358 D1 DE 60028358D1
- Authority
- DE
- Germany
- Prior art keywords
- hmg1
- sepsis
- septic shock
- disclosed
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/067—Pancreatitis or colitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
- G01N2800/125—Adult respiratory distress syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/248,574 US6303321B1 (en) | 1999-02-11 | 1999-02-11 | Methods for diagnosing sepsis |
US248574 | 1999-02-11 | ||
PCT/US2000/003583 WO2000047104A2 (en) | 1999-02-11 | 2000-02-11 | Antagonists of hmg1 for treating inflammatory conditions |
EP00915762.9A EP1165110B2 (de) | 1999-02-11 | 2000-02-11 | Hmg1 antagonisten zur behandlung von entzündungen |
Publications (3)
Publication Number | Publication Date |
---|---|
DE60028358D1 true DE60028358D1 (de) | 2006-07-06 |
DE60028358T2 DE60028358T2 (de) | 2007-03-29 |
DE60028358T3 DE60028358T3 (de) | 2017-03-30 |
Family
ID=22939703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60028358.5T Expired - Lifetime DE60028358T3 (de) | 1999-02-11 | 2000-02-11 | Hmg1 antagonisten zur behandlung von entzündungen |
Country Status (11)
Country | Link |
---|---|
US (12) | US6303321B1 (de) |
EP (4) | EP1165110B2 (de) |
JP (3) | JP4812166B2 (de) |
AT (1) | ATE327764T1 (de) |
AU (1) | AU782984B2 (de) |
CA (1) | CA2359926C (de) |
DE (1) | DE60028358T3 (de) |
DK (1) | DK1165110T3 (de) |
ES (1) | ES2269118T5 (de) |
PT (1) | PT1165110E (de) |
WO (1) | WO2000047104A2 (de) |
Families Citing this family (127)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6387639B1 (en) * | 1998-11-10 | 2002-05-14 | Sloan-Kettering Institute For Cancer Research | Ma family polypeptides and anti-Ma antibodies |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7151082B2 (en) * | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US20060154319A1 (en) * | 1999-04-29 | 2006-07-13 | Flodgaard Hans J | Inhibition of bradykinin release |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US7754217B2 (en) * | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
KR20040018370A (ko) * | 2001-05-15 | 2004-03-03 | 노쓰 쇼어-롱 아일랜드 제위시 리서치 인스티튜트 | Hmg 단편의 항염증제로서의 용도 |
US7220723B2 (en) * | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
US7026121B1 (en) | 2001-06-08 | 2006-04-11 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US7235358B2 (en) | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US6905827B2 (en) | 2001-06-08 | 2005-06-14 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases |
JP5055598B2 (ja) * | 2001-07-13 | 2012-10-24 | 株式会社シノテスト | ヒトhmg−1に特異的に結合する抗体を用いるヒトhmg−1の免疫学的測定方法及び免疫学的測定試薬 |
ITMI20011986A1 (it) * | 2001-09-25 | 2003-03-25 | San Raffaele Centro Fond | Metodo e composizione per l'attivazione di cellule presentanti l'antigene |
US7465555B2 (en) * | 2002-04-02 | 2008-12-16 | Becton, Dickinson And Company | Early detection of sepsis |
CA2491321A1 (en) | 2002-07-03 | 2004-01-15 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
CA2491026A1 (en) * | 2002-07-05 | 2004-01-15 | The University Of British Columbia | Diagnosis of sepsis using mitochondrial nucleic acid assays |
GB0226251D0 (en) * | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
AU2003291483A1 (en) | 2002-11-12 | 2004-06-03 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
WO2004043236A2 (en) * | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
EP1573054A4 (de) * | 2002-11-12 | 2005-12-28 | Becton Dickinson Co | Sepsis- oder sirs-diagnose mittels biomarkerprofilen |
US20040141948A1 (en) * | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
US20060121047A1 (en) * | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
US20040156851A1 (en) * | 2002-11-20 | 2004-08-12 | Critical Therapeutics, Inc. | HMGB1 combination therapies |
JP2006510619A (ja) * | 2002-11-20 | 2006-03-30 | クリティカル セラピューティクス,インコーポレイテッド | 抗炎症剤としてのhmgb断片の使用 |
ES2293086T3 (es) | 2002-12-06 | 2008-03-16 | The Feinstein Institute For Medical Research | Inhibicion de la inflamacion usando agonistas colinergicos de union al receptor alfa 7. |
WO2004079368A2 (en) | 2003-03-08 | 2004-09-16 | Auvation Ltd | Markers for colorectal cancer |
US7892745B2 (en) | 2003-04-24 | 2011-02-22 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US20090069227A9 (en) * | 2003-04-29 | 2009-03-12 | Capogrossi Maurizio C | Use of HMGB1 to promote stem cell migration and/or proliferation |
FR2855832B1 (fr) * | 2003-06-03 | 2007-09-14 | Biomerieux Sa | Procede de diagnostic et/ou de pronostic d'un syndrome septique |
US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
CA2538763C (en) | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
US20070269437A1 (en) * | 2003-09-19 | 2007-11-22 | Leukotech A/S | Pro-Inflammatory and Anti-Inflammatory Antibodies Against the Heparin-Binding Protein (Hbp) |
CA2537668A1 (en) * | 2003-09-29 | 2005-04-14 | Biosite Incorporated | Methods and compositions for the diagnosis of sepsis |
US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
US20050196817A1 (en) * | 2004-01-20 | 2005-09-08 | Molecular Staging Inc. | Biomarkers for sepsis |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2007530586A (ja) | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
WO2006083301A2 (en) * | 2004-06-17 | 2006-08-10 | Medimmune, Inc. | Immunogenic compositions comprising hmgb1 polypeptides |
WO2006012373A2 (en) * | 2004-07-20 | 2006-02-02 | Critical Therapeutics, Inc. | Combination therapies of hmgb and complement inhibitors against inflammation |
KR101249287B1 (ko) * | 2004-09-03 | 2013-04-01 | 크리어빌리스 쎄라퓨틱스 에스.피.에이. | 인간 및 비인간 hmgb1 boxa의 단백질분해효소내성 돌연변이 및 그들의 치료/진단 용도 |
WO2006029184A2 (en) | 2004-09-08 | 2006-03-16 | Expression Diagnostics, Inc. | Genes useful for diagnosing and monitoring inflammation related disorders |
CN101132811B (zh) | 2004-10-22 | 2012-05-30 | 米迪缪尼有限公司 | 抗hmgb1的高亲和力抗体及其用法 |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
US20080050832A1 (en) * | 2004-12-23 | 2008-02-28 | Buechler Kenneth F | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
AU2005323463B2 (en) | 2004-12-27 | 2009-11-19 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
US20060157647A1 (en) * | 2005-01-18 | 2006-07-20 | Becton, Dickinson And Company | Multidimensional liquid chromatography/spectrometry |
ITRM20050032A1 (it) * | 2005-01-21 | 2006-07-22 | Marco E Bianchi | Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica. |
FR2881437B1 (fr) | 2005-01-31 | 2010-11-19 | Biomerieux Sa | Procede pour le diagnostic/pronostic d'un syndrome septique |
KR20080006617A (ko) | 2005-04-15 | 2008-01-16 | 백톤 디킨슨 앤드 컴퍼니 | 패혈증의 진단 |
US20100040607A1 (en) * | 2005-05-13 | 2010-02-18 | Tracey Kevin J | Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases |
WO2006138429A2 (en) | 2005-06-16 | 2006-12-28 | The Feinstein Institute For Medical Research | Antibodies against hmgb1 and fragments thereof |
KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
US20100040608A1 (en) * | 2005-07-18 | 2010-02-18 | Marie Wahren-Herlenius | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions |
WO2007031100A1 (en) * | 2005-09-14 | 2007-03-22 | Ostini, Marco | Active immunotherapy of life-threatening systemic inflammation |
JP3876325B1 (ja) * | 2005-10-24 | 2007-01-31 | 国立大学法人 岡山大学 | 脳梗塞抑制剤 |
US20100172909A1 (en) * | 2005-10-24 | 2010-07-08 | Masahiro Nishibori | Cerebral edema suppressant |
US20080311122A1 (en) * | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
WO2007130725A2 (en) | 2006-02-06 | 2007-11-15 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of hmgb1 for protection against ischemia reperfusion injury |
US7986727B2 (en) * | 2006-03-28 | 2011-07-26 | Globalfoundries Inc. | In-band method to configure equalization levels |
US8570881B2 (en) * | 2006-03-28 | 2013-10-29 | Advanced Micro Devices, Inc. | Transmitter voltage and receiver time margining |
JP3882090B1 (ja) | 2006-05-19 | 2007-02-14 | 国立大学法人 岡山大学 | 脳血管攣縮抑制剤 |
US7993832B2 (en) | 2006-08-14 | 2011-08-09 | Xdx, Inc. | Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders |
KR101057844B1 (ko) * | 2006-09-20 | 2011-08-19 | 아사히 가세이 케미칼즈 가부시키가이샤 | 폴리올레핀 미다공막 및 비수전해액 전지용 세퍼레이터 |
US8148067B2 (en) | 2006-11-09 | 2012-04-03 | Xdx, Inc. | Methods for diagnosing and monitoring the status of systemic lupus erythematosus |
WO2008099917A1 (ja) * | 2007-02-15 | 2008-08-21 | Fukuoka University | 抗hmgb-1抗体を含む臓器移植拒絶抑制剤 |
US8470325B2 (en) * | 2007-02-15 | 2013-06-25 | Kagoshima University | Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody |
WO2008099920A1 (ja) | 2007-02-15 | 2008-08-21 | Kyushu University, National University Corporation | 抗hmgb-1抗体を含む間質性肺疾患治療剤 |
US20090004755A1 (en) * | 2007-03-23 | 2009-01-01 | Biosite, Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US8221995B2 (en) * | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
US20100255513A1 (en) * | 2007-03-30 | 2010-10-07 | Denson Lee A | Serological markers of inflammatory bowel disease phenotype and disease progression |
GB0711327D0 (en) | 2007-06-12 | 2007-07-25 | Hansa Medical Ab | Diagnostic method |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
WO2009033050A1 (en) * | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth Sys Tem Of Higher Education | Diagnostic and therapeutic uses of augmenter of liver regeneration in inflammatory conditions |
JP5224325B2 (ja) * | 2007-10-15 | 2013-07-03 | 国立大学法人 岡山大学 | B細胞悪性リンパ腫治療薬 |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009123737A2 (en) | 2008-04-03 | 2009-10-08 | Becton, Dickinson And Company | Advanced detection of sepsis |
CN102215909B (zh) | 2008-11-18 | 2014-09-10 | 赛博恩特医疗器械公司 | 优化用于消炎刺激的电极放置的装置和方法 |
JP2012513591A (ja) * | 2008-12-22 | 2012-06-14 | ザ チルドレンズ リサーチ インスティテュート | 敗血症の検出のための方法 |
US8612002B2 (en) | 2009-12-23 | 2013-12-17 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
US20110123483A1 (en) * | 2009-11-23 | 2011-05-26 | Deutsches Krebsforschungszentrum | Hmgb1 for cancer treatment |
EP2365332B1 (de) * | 2010-03-10 | 2013-05-29 | Institut Pasteur | HMGB1- und anti-HMGB1-Antikörper bei HIV-infizierten Patienten, insbesondere mit neurologischen Störungen |
EP2552944B1 (de) | 2010-03-29 | 2019-08-14 | University Of Southern California | Zusammensetzungen und verfahren zur brechungsbeseitigung von biofilmen |
WO2011127176A2 (en) * | 2010-04-06 | 2011-10-13 | The Children's Research Institute | Methods for treating or screening for compounds for the treatment of sepsis |
WO2011129382A1 (en) | 2010-04-16 | 2011-10-20 | Abbott Japan Co. Ltd. | Methods and reagents for diagnosing rheumatoid arthritis |
IT1406051B1 (it) | 2010-08-05 | 2014-02-06 | D M G Italia S R L | Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo. |
JP6012603B2 (ja) | 2010-09-09 | 2016-10-25 | ユニバーシティー オブ サザン カリフォルニア | バイオフィルムを除去するための組成物および方法 |
GB201016161D0 (en) | 2010-09-24 | 2010-11-10 | Hansa Medical Ab | Diagnostic method |
GB201102108D0 (en) | 2011-02-07 | 2011-03-23 | Hansa Medical Ab | Diagnostic method |
CN103619405B (zh) | 2011-05-09 | 2015-11-25 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活 |
WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
WO2012170740A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
DK3369742T3 (da) * | 2011-10-05 | 2020-10-19 | Univ Rockefeller | Dimere bakteriofaglysiner |
US20130171659A1 (en) * | 2011-12-28 | 2013-07-04 | Abbott Japan Co., Ltd. | Methods of prognosis and diagnosis of rheumatoid arthritis |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
US20150335763A1 (en) * | 2013-01-09 | 2015-11-26 | The Feinstein Institute For Medical Research | Hmgb1-binding beads and uses thereof |
EP2949675B1 (de) | 2013-01-28 | 2021-03-31 | Evec Inc. | Humanisierte anti-hmgb1-antikörper oder antigenbindendes fragment davon |
US11274144B2 (en) | 2013-06-13 | 2022-03-15 | Research Institute At Nationwide Children's Hospital | Compositions and methods for the removal of biofilms |
US9745366B2 (en) | 2013-09-23 | 2017-08-29 | University Of Southern California | Compositions and methods for the prevention of microbial infections |
US10233234B2 (en) | 2014-01-13 | 2019-03-19 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
US11248040B2 (en) | 2013-09-26 | 2022-02-15 | Trellis Bioscience, Llc | Binding moieties for biofilm remediation |
US9840555B2 (en) | 2013-11-04 | 2017-12-12 | Li-Te Chin | Method for producing human monoclonal antibodies that binds to at least one part of HMGB1 |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
WO2017023863A1 (en) | 2015-07-31 | 2017-02-09 | Research Institute At Nationwide Children's Hospital | Peptides and antibodies for the removal of biofilms |
JP7107839B2 (ja) | 2015-12-11 | 2022-07-27 | ルプレヒト-カールス-ウニベルジテート ハイデルベルク | Pkm2モジュレーター及びhmgb1の組合せ製剤 |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
EP3405255A4 (de) | 2016-01-20 | 2019-10-16 | Setpoint Medical Corporation | Implantierbare mikrostimulatoren und induktive ladesysteme |
US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US11746136B2 (en) | 2017-03-15 | 2023-09-05 | Research Institute At Nationwide Children's Hospital | Composition and methods for disruption of bacterial biofilms without accompanying inflammation |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
JP7313659B2 (ja) * | 2019-03-12 | 2023-07-25 | 株式会社シノテスト | 試料中のhmgb1の測定方法及び測定試薬 |
US11471507B2 (en) | 2019-05-09 | 2022-10-18 | The Feinstein Institutes For Medical Research | HMGB1 antagonist |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
JP7207772B2 (ja) | 2021-04-23 | 2023-01-18 | 株式会社タイセン工業 | 仮設橋ユニット |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4678772A (en) * | 1983-02-28 | 1987-07-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions containing glycyrrhizin |
JPS6032714A (ja) * | 1983-08-01 | 1985-02-19 | Teijin Ltd | 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物 |
US5585344A (en) | 1984-03-19 | 1996-12-17 | The Rockefeller University | Liver-derived receptors for advanced glycosylation endproducts and uses thereof |
JPS62166897A (ja) * | 1986-01-20 | 1987-07-23 | Toyo Soda Mfg Co Ltd | 核内非ヒストン蛋白質に対するモノクロ−ナル抗体 |
JPS63135351A (ja) * | 1986-11-28 | 1988-06-07 | Sanwa Kagaku Kenkyusho Co Ltd | グリチルレチン酸誘導体、その製法及び該化合物を有効成分とする抗潰瘍剤 |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
JP2998287B2 (ja) * | 1991-03-13 | 2000-01-11 | 千寿製薬株式会社 | グリチルレチン酸誘導体 |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
IT1253431B (it) | 1991-12-02 | 1995-08-08 | Valetudo S R L | Preparati farmaceutici per uso topico destinati al trattamento della psoriasi e della dermatite atopica |
IT1254321B (it) * | 1992-04-10 | 1995-09-14 | Kemiprogress S R L | Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale. |
GB9217316D0 (en) | 1992-08-14 | 1992-09-30 | Ludwig Inst Cancer Res | Schwann cell mitogenic factor,its preparation and use |
EP0727487A1 (de) † | 1995-02-17 | 1996-08-21 | K.U. Leuven Research & Development | Multi-Tumor abweichende Wachstumsgene |
JP3472048B2 (ja) | 1995-10-09 | 2003-12-02 | 鐘淵化学工業株式会社 | 自己免疫疾患の診断薬 |
DE19548122A1 (de) | 1995-12-21 | 1997-06-26 | Joern Prof Dr Bullerdiek | Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben |
US6323329B1 (en) | 1995-12-21 | 2001-11-27 | Jorn Bullerdiek | Nucleic acid sequences of genes encoding high mobility group proteins |
US5864018A (en) | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
US6720472B2 (en) | 1996-07-12 | 2004-04-13 | University Of Medicine And Dentistry Of New Jersey | HMGI proteins in cancer and obesity |
US6171779B1 (en) | 1996-07-12 | 2001-01-09 | University Of Medicine & Dentistry Of New Jersey | HMGI proteins in cancer |
WO1998002744A1 (fr) | 1996-07-17 | 1998-01-22 | Kaneka Corporation | Medicaments pour le diagnostic de maladies auto-immunes |
US7258857B2 (en) | 1996-11-22 | 2007-08-21 | The Trustees Of Columbia University In The City Of New York | Rage-related methods for treating inflammation |
JP2002514083A (ja) | 1997-05-07 | 2002-05-14 | シェーリング コーポレイション | ヒトToll様レセプタータンパク質、関連する試薬および方法 |
US20030032090A1 (en) | 1997-05-07 | 2003-02-13 | Schering Corporation, A New Jersey Corporation | Human receptor proteins; related reagents and methods |
IT1291366B1 (it) * | 1997-05-14 | 1999-01-07 | Angelini Ricerche Spa | Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale |
AU1070399A (en) | 1997-10-17 | 1999-05-10 | Genentech Inc. | Human toll homologues |
US20030027260A1 (en) | 1997-10-17 | 2003-02-06 | Genentech, Inc. | Human Toll homologues |
ES2137125B1 (es) | 1997-11-18 | 2000-08-16 | Vinyals S A Lab Dr | La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal. |
US6783961B1 (en) * | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
IT1299583B1 (it) | 1998-05-19 | 2000-03-16 | Vander Way Limited | Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica |
EP1121454B1 (de) | 1998-10-06 | 2007-11-14 | The Trustees of Columbia University in the City of New York | Extrazelluläres, neues rage-bindendes protein (en-rage) und dessen verwendungen |
US6303321B1 (en) | 1999-02-11 | 2001-10-16 | North Shore-Long Island Jewish Research Institute | Methods for diagnosing sepsis |
US7151082B2 (en) | 1999-02-11 | 2006-12-19 | The Feinstein Institute For Medical Research | Antagonists of HMG1 for treating inflammatory conditions |
US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
TWI221082B (en) | 1999-04-14 | 2004-09-21 | Sumitomo Chemical Co | Pesticidal compositions |
AU5320700A (en) | 1999-06-04 | 2000-12-28 | Millennium Pharmaceuticals, Inc. | Novel toll molecules and uses therefor |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
GB9927332D0 (en) | 1999-11-18 | 2000-01-12 | Leiv Eiriksson Nyfotek As | Novel antibody and uses thereof |
US6677321B1 (en) | 1999-12-09 | 2004-01-13 | Bruce Levin | Methods and compositions for treatment of inflammatory disease |
GB0001704D0 (en) | 2000-01-25 | 2000-03-15 | Glaxo Group Ltd | Protein |
US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
WO2001072993A1 (fr) | 2000-03-31 | 2001-10-04 | Mochida Pharmaceutical Co., Ltd. | Inhibiteur de liaison entre le recepteur de type toll et cd14 |
JP2001322276A (ja) * | 2000-05-15 | 2001-11-20 | Fuji Xerox Co Ltd | インクジェット記録ヘッド、インクジェット記録装置及びヘッド作製方法 |
EP1283849A2 (de) | 2000-05-25 | 2003-02-19 | Schering Corporation | Menschlische-rezeptor proteine; verwandte reagenzien und methoden |
GB0015325D0 (en) | 2000-06-22 | 2000-08-16 | Danionics As | Electrochemical cells |
WO2002070007A1 (en) | 2001-03-02 | 2002-09-12 | Medimmune, Inc. | Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
CA2440037C (en) | 2001-03-05 | 2010-02-16 | Transtech Pharma, Inc. | Benzimidazole derivatives for modulating the rage receptor |
JP2005500254A (ja) | 2001-03-05 | 2005-01-06 | トランス テック ファーマ,インコーポレイテッド | 治療因子としてのカルボキサミド誘導体 |
EP1379230A4 (de) | 2001-03-15 | 2009-01-21 | Univ Pittsburgh | Verfahren zur verwendung von pyruvat und/oder seiner derivative zur behandlung von durch zytokine vermittelten entzündlichen zuständen |
US7754217B2 (en) | 2001-03-16 | 2010-07-13 | Bio3 Research Srl | HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases |
US7078048B2 (en) | 2001-05-09 | 2006-07-18 | The Regents Of The University Of Michigan | Method and compositions for treating rosacea |
WO2002090520A2 (en) | 2001-05-09 | 2002-11-14 | Yale University | Toll/interleukin-1 receptor adaptor protein (tirap) |
US7304034B2 (en) | 2001-05-15 | 2007-12-04 | The Feinstein Institute For Medical Research | Use of HMGB fragments as anti-inflammatory agents |
KR20040018370A (ko) | 2001-05-15 | 2004-03-03 | 노쓰 쇼어-롱 아일랜드 제위시 리서치 인스티튜트 | Hmg 단편의 항염증제로서의 용도 |
US7220723B2 (en) | 2001-05-15 | 2007-05-22 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
JP4823465B2 (ja) | 2001-07-13 | 2011-11-24 | 株式会社シノテスト | ヒトhmg−1に特異的に結合する抗体並びにこの抗体を用いるヒトhmg−1の免疫学的測定方法及び免疫学的測定試薬 |
US20030032674A1 (en) | 2001-08-13 | 2003-02-13 | Hwang Daniel H. | Use of unsaturated fatty acids to treat severe inflammatory diseases |
WO2003022296A1 (en) | 2001-09-07 | 2003-03-20 | The Trustees Of Boston University | Method and composition for treating immune complex associated disorders |
JP2003088388A (ja) | 2001-09-14 | 2003-03-25 | Herikkusu Kenkyusho:Kk | 新規な全長cDNA |
EP1293566A1 (de) * | 2001-09-17 | 2003-03-19 | Societe Des Produits Nestle S.A. | Ein löslicher Toll-ähnlicher Rezeptor |
AU2002364607A1 (en) | 2001-12-28 | 2003-07-24 | The Burnham Institute | Novel ligand involved in the transmigration of leukocytes . |
DK1482931T3 (da) | 2002-03-05 | 2011-12-19 | Transtech Pharma Inc | Mono- og bicycliske azolderivater der inhiberer interaktionen af ligander med RAGE |
CA2491321A1 (en) | 2002-07-03 | 2004-01-15 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
GB0226251D0 (en) | 2002-11-11 | 2002-12-18 | San Raffaele Centro Fond | Acetylated protein |
JP2006510619A (ja) | 2002-11-20 | 2006-03-30 | クリティカル セラピューティクス,インコーポレイテッド | 抗炎症剤としてのhmgb断片の使用 |
US20060121047A1 (en) | 2002-11-20 | 2006-06-08 | Tracey Kevin J | Use of hmgb polypetides for increasing immune responses |
US20040141948A1 (en) | 2002-11-20 | 2004-07-22 | Critical Therapeutics, Inc. | Use of HMGB fragments as anti-inflammatory agents |
US7696169B2 (en) * | 2003-06-06 | 2010-04-13 | The Feinstein Institute For Medical Research | Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents |
CA2538763C (en) * | 2003-09-11 | 2015-05-05 | Critical Therapeutics, Inc. | Monoclonal antibodies against hmgb1 |
WO2005034952A2 (en) | 2003-10-07 | 2005-04-21 | The Feinstein Institute For Medical Research | Isoxazole and isothiazole compounds useful in the treatment of inflammation |
WO2006083301A2 (en) | 2004-06-17 | 2006-08-10 | Medimmune, Inc. | Immunogenic compositions comprising hmgb1 polypeptides |
CA2574548A1 (en) | 2004-07-20 | 2006-01-26 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb1 for wound healing |
EP1771565B1 (de) | 2004-07-20 | 2012-09-05 | The Feinstein Institute for Medical Research | Rage protein derivate |
US7981423B2 (en) | 2004-08-03 | 2011-07-19 | Transtech Pharma, Inc. | Rage fusion proteins |
KR101249287B1 (ko) | 2004-09-03 | 2013-04-01 | 크리어빌리스 쎄라퓨틱스 에스.피.에이. | 인간 및 비인간 hmgb1 boxa의 단백질분해효소내성 돌연변이 및 그들의 치료/진단 용도 |
US8129130B2 (en) | 2004-10-22 | 2012-03-06 | The Feinstein Institute For Medical Research | High affinity antibodies against HMGB1 and methods of use thereof |
CN101132811B (zh) | 2004-10-22 | 2012-05-30 | 米迪缪尼有限公司 | 抗hmgb1的高亲和力抗体及其用法 |
US20100040608A1 (en) | 2005-07-18 | 2010-02-18 | Marie Wahren-Herlenius | Use of HMGB1 antagonists for the treatment of inflammatory skin conditions |
CA2628546A1 (en) | 2005-11-09 | 2007-05-18 | Pharmexa A/S | Therapeutic vaccines targeting hmgb1 |
US20080311122A1 (en) | 2005-11-28 | 2008-12-18 | Medimmune, Llc | Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof |
SG174782A1 (en) | 2006-09-08 | 2011-10-28 | Abbott Lab | Interleukin - 13 binding proteins |
WO2008076758A2 (en) * | 2006-12-13 | 2008-06-26 | William Marsh Rice University | Nerolidol, terpene, and terpene derivative synthesis |
US20100249038A1 (en) | 2007-06-12 | 2010-09-30 | Board Of Regents, University Of Texas System | Antagonists of the receptor for advanced glycation end-products (rage) |
-
1999
- 1999-02-11 US US09/248,574 patent/US6303321B1/en not_active Expired - Lifetime
-
2000
- 2000-02-11 EP EP00915762.9A patent/EP1165110B2/de not_active Expired - Lifetime
- 2000-02-11 WO PCT/US2000/003583 patent/WO2000047104A2/en active IP Right Grant
- 2000-02-11 EP EP05077852A patent/EP1707214A1/de not_active Withdrawn
- 2000-02-11 AU AU36983/00A patent/AU782984B2/en not_active Expired
- 2000-02-11 EP EP20100075469 patent/EP2362221A1/de not_active Ceased
- 2000-02-11 PT PT00915762T patent/PT1165110E/pt unknown
- 2000-02-11 CA CA2359926A patent/CA2359926C/en not_active Expired - Lifetime
- 2000-02-11 AT AT00915762T patent/ATE327764T1/de active
- 2000-02-11 DE DE60028358.5T patent/DE60028358T3/de not_active Expired - Lifetime
- 2000-02-11 JP JP2000598059A patent/JP4812166B2/ja not_active Expired - Lifetime
- 2000-02-11 ES ES00915762.9T patent/ES2269118T5/es not_active Expired - Lifetime
- 2000-02-11 EP EP06075291.2A patent/EP1757937B1/de not_active Expired - Lifetime
- 2000-02-11 DK DK00915762T patent/DK1165110T3/da active
- 2000-02-14 US US09/503,632 patent/US6468533B1/en not_active Expired - Lifetime
-
2001
- 2001-08-15 US US09/929,962 patent/US6448223B1/en not_active Expired - Lifetime
-
2002
- 2002-07-31 US US10/210,747 patent/US7097838B2/en not_active Expired - Lifetime
- 2002-09-11 US US10/242,056 patent/US7060504B2/en not_active Expired - Fee Related
-
2005
- 2005-12-01 US US11/292,320 patent/US7537908B2/en not_active Expired - Fee Related
-
2006
- 2006-06-29 US US11/477,835 patent/US7572446B2/en not_active Expired - Fee Related
-
2009
- 2009-04-13 US US12/386,053 patent/US8053206B2/en not_active Expired - Fee Related
- 2009-07-01 US US12/496,333 patent/US8138141B2/en not_active Expired - Fee Related
-
2011
- 2011-03-16 JP JP2011058031A patent/JP5745299B2/ja not_active Expired - Lifetime
-
2012
- 2012-02-22 US US13/402,057 patent/US8822169B2/en not_active Expired - Fee Related
-
2013
- 2013-11-22 JP JP2013241528A patent/JP2014031386A/ja active Pending
-
2014
- 2014-08-29 US US14/473,333 patent/US20150322140A1/en not_active Abandoned
-
2016
- 2016-01-21 US US15/002,688 patent/US20170129946A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE327764T1 (de) | Hmg1 antagonisten zur behandlung von entzündungen | |
Opp et al. | Interleukin-1 is involved in responses to sleep deprivation in the rabbit | |
Juhlin et al. | Cutaneous reactions to kallikrein, bradykinin and histamine in healthy subjects | |
ATE442592T1 (de) | Detektion und/oder beobachtung von synuclein- assoziierten krankheiten | |
CY1108947T1 (el) | Ανθεκτικη σε παραβιαση μορφη δοσολογιας συμπεριλαμβανουσα ενα προσροφητικο και εναν αντιθετο παραγοντα | |
HUP0301020A2 (hu) | Konformációs betegségek korai diagnosztikája | |
IL206829A (en) | Use of an antibody-containing homologue to prepare leukocyte-induced rise in bronchoalveolar fluid-related specimen | |
DE69925024D1 (de) | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten | |
SE9800550D0 (sv) | A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof | |
BR0314353A (pt) | Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio | |
EA199800690A1 (ru) | Замещенные n-[(аминоиминометил)фенилалкил]азагетероцикламиды сульфоновых кислот | |
EA199900542A1 (ru) | Соединения сульфоновой кислоты или сульфониламино-n-(гетероаралкил)-азагетероциклиламида | |
ATE181422T1 (de) | Verfahren zur diagnose von praeklampsie | |
ATE242005T1 (de) | P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes | |
DE69635305D1 (de) | Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma | |
ATE395433T1 (de) | Screeningverfahren für geeignete wirkstoffe | |
DE59914712D1 (de) | Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden | |
DE60334556D1 (de) | Chorionic gonadotropin zur Behandlung des chronischen Schmerzsyndroms des Beckens | |
ATE537823T1 (de) | Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin | |
DE69733169D1 (de) | Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs | |
ATE396737T1 (de) | Prophylaxe, behandlung und prognose/überwachung von sepsis und septischem schock | |
DE69623316T2 (de) | Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen | |
WO1998041238A3 (en) | Methods and kits for treating and diagnosing leiomyomas | |
SE9801368D0 (sv) | New use | |
DE60117541D1 (de) | Candesartan zur Behandlung von Migräne |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8363 | Opposition against the patent |